Impacts of smoking status on the clinical outcomes of coronary non-target lesions in patients with coronary heart disease: a single-center angiographic study

Hao-Bo Xu, Juan Wang, Ji-Lin Chen, Chao Guo, Jian-Song Yuan, Xin Duan, Feng-Huan Hu, Wei-Xian Yang, Xiao-Liang Luo, Rong Liu, Jin-Gang Cui, Sheng-Wen Liu, Xiao-Jin Gao, Yu-Shi Chun, Shu-Bin Qiao

Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing 100037, China.

Abstract

Background: Coronary atherosclerotic plaque could go through rapid progression and induce adverse cardiac events. This study aimed to evaluate the impacts of smoking status on clinical outcomes of coronary non-target lesions.

Methods: Consecutive patients with coronary heart disease who underwent two serial coronary angiographies were included. All coronary non-target lesions were recorded at first coronary angiography and analyzed using quantitative coronary angiography at both procedures. Patients were grouped into non-smokers, quitters, and smokers according to their smoking status. Multivariable Cox regression analysis was used to investigate the association between smoking status and clinical outcomes.

Results: A total of 1255 patients and 1670 lesions were included. Smokers were younger and more likely to be male compared with non-smokers. Increase in percent diameter stenosis was significantly lower (2.7 [0.6, 7.1] % vs. 3.5 [0.9, 8.9] %) and 3.4 [1.1, 7.7] %, P = 0.020) in quitters than those in smokers and non-smokers. Quitters tended to have a decreased incidence of rapid lesion progression (15.8% [76/482] vs. 21.6% [74/342] and 20.6% [89/431], P = 0.062), lesion re-vascularization (13.1% [63/482] vs. 15.5% [53/342] and 15.5% [67/431], P = 0.448), lesion-related myocardial infarction (0.8% [4/482] vs. 2.6% [9/342] and 1.4% [6/431], P = 0.110) and all-cause myocardial infarction (1.9% [9/482] vs. 4.1% [14/342] and 2.3% [10/431], P = 0.128) compared with smokers and non-smokers. In multivariable analysis, smoking status was not an independent predictor for rapid lesion progression, lesion re-vascularization, and lesion-related myocardial infarction except that a higher risk of all-cause myocardial infarction was observed in smokers than non-smokers (hazard ratio: 2.7 [0.6, 7.1] % vs. 2.5 [0.8, 7.1] %, P = 0.020).

Conclusion: Smoking cessation mitigates the increase in percent diameter stenosis of coronary non-target lesions, meanwhile, smokers are associated with increased risk for all-cause myocardial infarction compared with non-smokers.

Keywords: Smoking status; Coronary non-target lesion; Rapid progression; Re-vascularization; Myocardial infarction

Introduction
Coronary heart disease (CHD) is a major cause of death in both developed and developing countries. Smoking is one of the most important causes of CHD. The number of smokers worldwide is currently estimated to be 1.3 billion, of which 82% are in developing countries, for example, China. Cigarette use contributes to the initiation and progression of coronary atherosclerosis independently of other traditional risk factors. However, smoking tends to have long-term adverse effects on coronary lesions, whether changes in smoking status affect clinical outcomes of coronary lesions in a relatively short period of time is still unknown. It has recently been noted that coronary atherosclerosis could progress in a short period of time over few months to 2 to 3 years. Rapid progression of coronary lesion leads to acute myocardial ischemia and is usually unpredictable. The aim of this study was to investigate the effects of smoking status on rapid progression of coronary lesions as well as the incidence of adverse outcomes due to this process in patients with CHD.

Methods

Ethical approval

The study complied with the principles of the Declaration of Helsinki and was approved by the Review Board of
Study population
This was a single center, retrospective study. A total of 1607 consecutive patients with CHD (acute coronary syndrome or stable angina) who underwent two serial coronary angiographies (CAGs) at Fuwai Hospital were enrolled from January 2010 to September 2014. Percutaneous coronary intervention (PCI) was performed at the operator’s discretion after first CAG. Second CAG was conducted because of clinical symptoms or an abnormal stress test with myocardial ischemia or routine angiographic follow-up. Patients with the second CAG performed within 2 years after the first CAG were included. The 338 patients were excluded because there was no non-target lesion recorded at the first CAG. Patients were also excluded as follows: two patients had a history of coronary artery bypass graft surgery before first CAG; three patients had active malignant tumor; and nine patients had a follow-up period longer than 2 years. No patient had clinically significant valvular heart disease, serious conduction disturbances, significant arrhythmias, and renal dysfunction. Thus, 1255 patients were finally included in this study. Patients were grouped according to their smoking status as described below. A total of 1670 coronary non-target lesions were recorded at the first CAG. All study patients received standard medicine therapy including statins, aspirin, clopidogrel or ticagrelor, beta-blockers, angiotensin converting enzyme inhibitors/angiotensin receptor blockers, calcium channel blockers, and oral nitrates after the initial admission. Data including demographic information, medical history, CHD risk factors, detailed coronary angiographic information, and biomarkers associated with coronary atherosclerosis were collected at two consecutive coronary angiographic procedures.

Process of coronary angiography and quantitative coronary angiography measurement
Selective CAG was performed following the administration of intracoronary glyceryl nitrate. The assessment of rapid angiographic lesion progression was achieved by comparing the data from quantitative coronary angiography (QCA) at both CAG procedures. Each pair of coronary angiograms was obtained in the same projection and quantitatively assessed by two independent cardiologists who were unaware of all other clinical data of the patients. During quantitative CAG, the stem of the Judkins coronary catheter was used for calibration to determine absolute measurements in millimeters, and correction was made for radiographic pincushion distortion. For each segment, measurements were carried out on end-diastolic frames in which the severity of the stenosis appeared maximal. Reference diameter, lesion length, minimal lumen diameter and percent diameter stenosis were measured.

Definitions
Coronary non-target lesion was defined as a de novo stenotic lesion that was not responsible for ischemic symptoms or any positive functional ischemic test as previously described. Rapid lesion progression was interpreted from the increase in percent diameter stenosis calculated using percent diameter stenosis at second CAG minus that at first CAG. Rapid progression was defined based on previous reported criteria which included the presence of any of the following: ≥10% diameter reduction of a pre-existing stenosis ≥30%, ≥30% diameter reduction of a pre-existing stenosis <30%, or progression of any lesion to total occlusion at second CAG. When at least one lesion showed rapid progression, the patient was considered as a progressor. Lesion re-vascularization at the second CAG was performed in lesions which were responsible for ischemic symptoms or had positive results on functional ischemia study. Clinical outcomes including rapid lesion progression, lesion re-vascularization, lesion-related myocardial infarction, as well as all-cause myocardial infarction were documented at second CAG.

Smoking status
Patients were divided into three groups on the basis of smoking information provided by the patients at both CAG procedures. Smoking status was defined in accordance with previously reported definition. Briefly, non-smokers were defined as patients who had never smoked before or after the CAG procedure. Quitters were defined as those who had quit smoking either before or instantly after the first CAG. Persistent smokers were defined as patients who smoked before the first CAG and continued to smoking till the second CAG. Patients with reduced cigarette consumption after the first CAG were regarded as persistent smokers.

Statistical analysis
The results are expressed as mean ± standard deviation, median (Q1, Q3), or number (percentage). Continuous variables were tested for normal distribution with the Kolmogorov-Smirnov test. Differences in continuous variables were initially evaluated by one-way analysis of variance, and then by Tukey post-hoc test if appropriate. If variables were not normally distributed, the Kruskal-Wallis H test was performed. Categorical data were analyzed using Chi-squared test or Fisher exact test when required. A multivariable Cox proportional hazards model was used to evaluate the association between smoking status and study end points. Variables were included because of their known clinical importance or because univariate comparisons showed P < 0.15. The variables included age, sex, ST-segment elevation myocardial infarction (STEMI), hypertension, diabetes mellitus, baseline low-density lipoprotein cholesterol, C-reactive protein (CRP), and erythrocyte sedimentation rate. A P < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 19.0 (IBM, Armonk, NY, USA). A P < 0.05 was considered to be statistically significant.

Results

Clinical characteristics
A total of 1255 patients with CHD were evaluated in this study. Patients were divided into three groups according to their smoking manners: non-smokers (431 patients),
quitters (482 patients), and smokers (342 patients). Clinical characteristics among groups are summarized in Table 1. Smokers and quitters were younger, more likely to be male and had a less prevalence of hypertension compared with non-smokers. Compared with quitters and smokers, the prevalence of STEMI and history of myocardial infarction were lower in non-smoker. The proportions of patients with three-vessel disease were similar among groups. There was no significant difference in medication therapy at discharge. Non-smokers were associated with decreased levels of white blood cells and CRP and increased level of total cholesterol at both CAG procedures. There was no remarkable significance in levels of N-terminal pro-B-type natriuretic peptide and hemoglobin A1c among groups.

Angiographic studies of coronary non-target lesions

A total of 1670 non-target lesions were documented at the first CAG: 578 lesions in non-smokers, 625 lesions in quitters, and 467 lesions in smokers. Lesion distribution, location, and classification were not significantly different among three groups [Table 2]. Lesion characteristics such as lesion length, morphology, and contour as well as tortuosity, angulation, calcification, and bifurcation were also similar among three groups. QCA analysis showed that quitters had a larger reference diameter and minimal lumen diameter compared with non-smokers and smokers at both CAG procedures. Although percent diameter stenosis was not different among groups, the increase of percent diameter stenosis at second CAG was significantly

### Table 1: Clinical characteristics of 1255 patients with CHD grouped by smoking status.

| Characteristics | Non-smokers (n = 431) | Quitters (n = 482) | Smokers (n = 342) | Statistical values | P |
|-----------------|-----------------------|-------------------|------------------|-------------------|---|
| Age (years)     | 60.3 ± 9.9            | 58.3 ± 9.5        | 54.8 ± 8.6       | 31.890∗          | <0.001 |
| Male            | 212 (49.2)            | 464 (96.3)        | 327 (95.6)       | 386.395†         | <0.001 |
| BMI (kg/m²)     | 26.0 ± 3.0            | 26.5 ± 3.2        | 26.3 ± 3.2       | 6.749∗           | 0.035  |
| Diabetes mellitus | 155 (36.0)        | 162 (33.6)        | 108 (31.6)       | 1.659†           | 0.436  |
| Hypertension    | 314 (72.9)            | 317 (65.8)        | 201 (58.8)       | 17.020†          | <0.001 |
| Dyslipidemia    | 292 (67.7)            | 314 (65.1)        | 229 (67.0)       | 0.731†           | 0.694  |
| Family history of CHD | 32 (7.4)           | 33 (6.8)          | 29 (8.5)         | 0.774†           | 0.679  |
| STEMI           | 39 (9.0)              | 79 (16.4)         | 52 (15.2)        | 11.576∗          | 0.003  |
| NSTEMI          | 10 (2.3)              | 12 (2.5)          | 8 (2.3)          | 0.033†           | 0.983  |
| Previous MI     | 69 (16.0)             | 112 (23.2)        | 66 (19.3)        | 7.562*           | 0.023  |
| Peripheral vascular disease | 44 (10.2)      | 51 (10.6)         | 28 (8.2)         | 1.420*           | 0.492  |
| Previous stroke | 40 (9.3)              | 49 (10.2)         | 29 (8.5)         | 0.679*           | 0.712  |
| Previous PCI    | 74 (17.2)             | 110 (22.8)        | 69 (20.2)        | 4.516*           | 0.105  |
| LVEF (%)        | 63.6 ± 6.5            | 61.8 ± 7.7        | 62.8 ± 6.8       | 7.247*           | 0.002  |
| Three-vessel disease | 250 (58.0)       | 256 (53.1)        | 197 (57.6)       | 1.843*           | 0.515  |
| Medication at discharge |                  |                   |                  |                  |       |
| Aspirin         | 427 (99.1)            | 478 (99.2)        | 341 (99.7)       | 0.104†           | 0.877  |
| P2Y12 receptor antagonist | 376 (87.2)        | 423 (87.8)        | 302 (88.3)       | 0.631†           | 0.718  |
| Statin          | 410 (95.1)            | 463 (96.1)        | 330 (96.5)       | 0.548‡           | 0.733  |
| Biochemistry examination (first CAG) |                  |                   |                  |                  |       |
| White blood cell (×10³/L) | 6.5 ± 1.7             | 6.9 ± 1.9         | 7.3 ± 1.9        | 14.042∗          | <0.001 |
| CRP (mg/L)      | 2.4 (1.5, 4.5)        | 2.8 (1.8, 4.8)    | 2.9 (1.7, 5.1)   | 8.696∗           | 0.013  |
| ESR (mm/H)      | 10.0 (5.0, 18.0)      | 6.0 (3.0, 11.0)   | 6.0 (2.0, 11.0)  | 56.162∗          | <0.001 |
| NT-pro BNP (pg/mL) | 699.9 ± 368.5       | 709.5 ± 482.0    | 705.2 ± 499.1   | 0.048∗           | 0.946  |
| TC (mmol/L)     | 4.5 ± 1.1             | 4.2 ± 1.0         | 4.4 ± 1.1        | 10.035∗          | <0.001 |
| LDL-C (mmol/L)  | 2.7 ± 1.0             | 2.5 ± 0.8         | 2.5 ± 0.9        | 6.608∗           | 0.005  |
| TG (mmol/L)     | 1.9 ± 1.1             | 1.8 ± 0.9         | 2.1 ± 1.7        | 5.992*           | 0.050  |
| HbA1c (%)       | 6.4 ± 1.2             | 6.4 ± 1.1         | 6.4 ± 1.1        | 0.288*           | 0.750  |
| Biochemistry examination (second CAG) |                  |                   |                  |                  |       |
| White blood cell (×10³/L) | 6.3 ± 1.5             | 6.5 ± 1.5         | 6.9 ± 1.7        | 32.027∗          | <0.001 |
| CRP (mg/L)      | 1.9 (1.3, 3.0)        | 1.8 (1.3, 3.3)    | 2.3 (1.4, 3.7)   | 10.354∗          | 0.006  |
| ESR (mm/H)      | 7.0 (3.0, 14.0)       | 4.0 (2.0, 8.0)    | 4.0 (2.0, 7.5)   | 72.224∗          | <0.001 |
| NT-pro BNP (pg/mL) | 618.7 ± 306.7       | 651.7 ± 445.2    | 623.4 ± 349.1   | 0.961∗           | 0.619  |
| TC (mmol/L)     | 4.1 ± 1.1             | 3.8 ± 0.9         | 4.0 ± 1.0        | 14.516∗          | 0.001  |
| LDL-C (mmol/L)  | 2.3 ± 0.9             | 2.2 ± 0.7         | 2.3 ± 0.8        | 4.032*           | 0.133  |
| TG (mmol/L)     | 1.7 ± 1.1             | 1.6 ± 0.8         | 1.9 ± 1.7        | 15.467∗          | <0.001 |
| HbA1c (%)       | 6.6 ± 1.1             | 6.5 ± 1.1         | 6.5 ± 1.0        | 1.011*           | 0.603  |

Data are represented as mean ± standard deviation, median (Q1, Q3) or n (%). ∗ F values. † χ² values. ‡ H values. CHD: Coronary heart disease; BMI: Body mass index; STEMI: ST-segment elevation myocardial infarction; NSTEMI: Non-ST-segment elevation myocardial infarction; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; LVEF: Left ventricular ejection fraction; CAG: Coronary angiography; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; NT-pro BNP: N-terminal pro-B-type natriuretic peptide; TC: Total cholesterol; LDL-C: Low-density lipoprotein cholesterol; TG: Triglyceride; HbA1c: Hemoglobin A1c.
Table 2: Lesion characteristics and QCA analysis of non-target lesions among three groups.

| Characteristics | Non-smokers (n = 578) | Quitters (n = 625) | Smokers (n = 467) | Statistical values | P |
|-----------------|-----------------------|-------------------|------------------|--------------------|---|
| Lesion Distribution |                        |                   |                  |                    |   |
| LM              | 1 (0.2)               | 1 (0.2)           | 0                |                    |   |
| LAD             | 204 (35.3)            | 228 (36.5)        | 169 (36.2)       |                    |   |
| LCX             | 158 (27.3)            | 140 (22.4)        | 129 (27.6)       |                    |   |
| RCA             | 197 (34.1)            | 231 (37.0)        | 152 (32.5)       |                    |   |
| DIA/OM          | 18 (3.1)              | 25 (4.0)          | 17 (3.6)         |                    |   |
| Lesion location |                        |                   |                  |                    |   |
| Proximal        | 258 (44.6)            | 286 (45.8)        | 188 (40.3)       |                    |   |
| Mid             | 207 (35.8)            | 241 (38.6)        | 199 (42.6)       |                    |   |
| Distal          | 113 (19.6)            | 98 (15.7)         | 80 (17.1)        |                    |   |
| Lesion classification |                 |                   |                  |                    |   |
| A + B1          | 212 (36.7)            | 242 (38.7)        | 165 (35.3)       |                    |   |
| B2 + C          | 366 (63.3)            | 383 (61.3)        | 302 (64.7)       |                    |   |
| Diffuse lesion  | 88 (15.2)             | 81 (13.0)         | 80 (17.1)        |                    |   |
| Eccentric lesion| 157 (27.2)            | 182 (29.1)        | 138 (29.6)       |                    |   |
| Tortuosity      | 102 (17.6)            | 114 (18.2)        | 85 (18.2)        |                    |   |
| Angulation      | 114 (19.7)            | 133 (21.3)        | 93 (19.9)        |                    |   |
| Irregular contour| 99 (17.1)             | 101 (16.2)        | 78 (16.7)        |                    |   |
| Lesion calcification |         |                   |                  |                    |   |
| Ostial lesion   | 43 (7.4)              | 47 (7.5)          | 32 (6.9)         |                    |   |
| Bifurcation     | 99 (17.1)             | 104 (16.6)        | 87 (18.6)        |                    |   |
| QCA analysis (baseline) |   |                   |                  |                    |   |
| Reference diameter (mm) | 2.8 ± 0.6           | 2.9 ± 0.6         | 2.8 ± 0.6        | 15.568†           | 0.001 |
| Lesions length (mm)      | 12.8 ± 7.4          | 12.7 ± 7.2        | 13.4 ± 7.5       | 1.207†            | 0.289 |
| Minimal lumen diameter (mm) | 1.7 ± 0.4          | 1.8 ± 0.5         | 1.8 ± 0.4        | 3.237†            | 0.040 |
| Percent diameter stenosis (%) | 37.7 ± 8.9       | 38.0 ± 9.2        | 37.9 ± 9.2       | 0.191†            | 0.889 |
| QCA analysis (follow-up) |            |                   |                  |                    |   |
| Reference diameter (mm) | 2.8 ± 0.6           | 2.9 ± 0.6         | 2.8 ± 0.6        | 11.361†           | 0.003 |
| Lesions length (mm)      | 14.8 ± 8.3          | 14.4 ± 8.1        | 15.0 ± 8.2       | 0.664†            | 0.727 |
| Minimal lumen diameter (mm) | 1.6 ± 0.5          | 1.7 ± 0.5         | 1.60 ± 0.5       | 5.771†            | 0.003 |
| Percent diameter stenosis (%) | 43.2 ± 12.6        | 41.8 ± 11.7       | 43.2 ± 13.4      | 3.209†            | 0.285 |
| Increase in percent diameter stenosis (%) | 3.4 (1.1, 7.7)   | 2.7 (0.6, 7.1)    | 3.5 (0.9, 8.9)   | 7.799†            | 0.020 |
| Rapid lesion progression | 92 (15.9)          | 80 (12.8)         | 79 (16.9)        | 4.091†            | 0.129 |
| Lesion re-vascularization | 67 (11.6)          | 65 (10.4)         | 55 (11.8)        | 0.648†            | 0.723 |
| Number of stents        | 1.3 ± 0.5           | 1.3 ± 0.6         | 1.3 ± 0.5        | 0.907†            | 0.635 |

Data are represented as mean ± standard deviation, median (Q1, Q3) or n (%). *P* values. †F values. QCA: Quantitative coronary angiography; LM: Left main; LAD: Left anterior descending artery; LCX: Left circumflex artery; RCA: Right coronary artery; DIA: Diagonal branch; OM: Obtuse marginal branch.

decreased in quitters compared with smokers and non-smokers (2.7 [0.6, 7.1]% vs. 3.5 [0.9, 8.9]% and 3.4 [1.1, 7.7]%, *P* = 0.020) [Figure 1]. A total of 251 lesions showed rapid progression at second CAG. At the lesion level, quitters tended to have a lower incidence of rapid lesion progression (12.8% [80/625] vs. 15.9% [92/578] and 16.9% [79/467], *P* = 0.129) and lesion re-vascularization (10.4% [63/625] vs. 11.6% [67/578] and 11.8% [55/467], *P* = 0.723) compared with non-smokers and smokers, but the results were not significantly different.

**Impacts of smoking status on clinical outcomes**

The clinical outcomes of coronary non-target lesions at the patient level were documented at the second CAG and are presented in Table 3. The incidence of rapid lesion progression in quitters were lower compared with smokers and non-smokers but results were not statistically significant (15.8% [76/482] vs. 21.6% [74/342] and 20.6% [89/431], *P* = 0.062). Quitters also had a lower incidence toward lesion re-vascularization, lesion-related myocardial infarction, and all-cause myocardial infarction compared with non-smokers and smokers though significant difference was not evident. The association between smoking status and clinical outcomes were investigated in Cox regression analysis [Table 4]. Results showed that smoking status was not an independent risk factor for clinical outcomes in univariable analysis (*P* > 0.05). Multivariable analysis showed that, after adjusting for age, sex, STEMI, hypertension, diabetes mellitus, baseline low-density lipoprotein cholesterol, CRP and erythrocyte sedimentation rate, smokers were at a higher risk for all-cause myocardial infarction compared to non-smokers (hazards ratio: 3.00, 95% confidence interval: 1.04–8.62, *P* = 0.042). Smoking status were not independent predictors for lesion progression, lesion re-vascularization, and lesion-related myocardial infarction (*P* > 0.05).
Discussion

In this study, impacts of smoking status on clinical outcomes of coronary non-target lesions were assessed angiographically in a single center. Our results showed that quitters had a significantly lower increase in percent diameter stenosis compared with smokers and non-smokers. Quitters also had lower incidence of rapid lesion progression compared with non-smokers and smokers both at lesion level and patient level though significant difference was not evident. Smoking status was not an independent risk factor for rapid lesion progression, lesion re-vascularization and lesion-related myocardial infarction in multivariable analysis but smokers were at a higher risk for all-cause myocardial infarction than non-smokers.

A plenty of evidence had showed that coronary plaques would go through a period of rapid progression weeks to months before developing to myocardial infarction.[12] Stone et al.[13] in the PROSPECT study found that among 106 non-culprit lesions in 697 patients resulting in subsequent acute coronary syndrome during median 3.4-year follow-up, there was rapid progression from a mean angiographic diameter stenosis of $32 \pm 21\%$ to $65 \pm 16\%$ at the time of acute events. In our study, two serial CAGs were all performed within 2 years. Changes of coronary lesions stenosis during this time course could be defined as rapid progression according to previous studies.[14] The onset of new lesions was not included because previous study showed that more than 95% of re-vascularization in non-target lesions was driven by preexisting lesions rather than new onset lesions.[15]

Identifying modifiable clinical factors resulting in rapid coronary lesion progression is of great importance. Smoking promotes coronary atherosclerosis and is one of the most important risk factors for CHD.[1,2] Previous

![Figure 1: Changes in percent diameter stenosis of coronary non-target lesion at the second coronary angiography among groups with different smoking status.](image)

| Clinical outcomes                        | Non-smokers ($n = 431$) | Quitters ($n = 482$) | Smokers ($n = 342$) | Statistical values | $P$ |
|-----------------------------------------|--------------------------|----------------------|---------------------|--------------------|-----|
| Follow-up interval (months)             | 14.2 ± 4.4               | 14.9 ± 5.3           | 14.0 ± 4.5          | 3.891$^*$           | 0.036 |
| Rapid lesion progression                | 89 (20.6)                | 76 (15.8)            | 74 (21.6)           | 5.569$^*$           | 0.062 |
| Lesion re-vascularization               | 67 (15.5)                | 63 (13.1)            | 53 (15.5)           | 1.435$^*$           | 0.488 |
| Lesion-related myocardial infarction    | 6 (1.4)                  | 4 (0.8)              | 9 (2.6)             | 4.421$^*$           | 0.110 |
| All-cause myocardial infarction         | 10 (2.3)                 | 9 (1.9)              | 14 (4.1)            | 4.118$^*$           | 0.128 |

$^*$F values. $^\dagger$X$^2$ values. Data are represented as mean ± standard deviation or $n$ (%).

| Outcomes                                | Smoking Status | Crude HR (95% CI) | Crude $P$ | Adjusted HR (95% CI) | Adjusted $P$ |
|-----------------------------------------|----------------|-------------------|-----------|----------------------|--------------|
| Rapid lesion progression                | Non-smokers    | Reference         | –         | Reference            | –            |
|                                         | Quitters       | 0.93 (0.68–1.27)  | 0.641     | 0.92 (0.64–1.32)     | 0.640        |
|                                         | Smokers        | 1.14 (0.84–1.55)  | 0.415     | 1.06 (0.73–1.53)     | 0.760        |
| Least re-vascularization                | Non-smokers    | Reference         | –         | Reference            | –            |
|                                         | Quitters       | 0.99 (0.70–1.40)  | 0.946     | 0.93 (0.62–1.38)     | 0.708        |
|                                         | Smokers        | 1.08 (0.76–1.54)  | 0.676     | 0.99 (0.66–1.50)     | 0.970        |
| Lesion-related myocardial infarction    | Non-smokers    | Reference         | –         | Reference            | –            |
|                                         | Quitters       | 0.58 (0.14–2.31)  | 0.436     | 1.15 (0.25–5.38)     | 0.861        |
|                                         | Smokers        | 2.12 (0.75–6.00)  | 0.155     | 3.30 (0.84–13.00)    | 0.088        |
| All-cause myocardial infarction         | Non-smokers    | Reference         | –         | Reference            | –            |
|                                         | Quitters       | 0.94 (0.37–2.40)  | 0.901     | 1.46 (0.48–4.46)     | 0.502        |
|                                         | Smokers        | 2.01 (0.89–4.35)  | 0.093     | 3.00 (1.04–8.62)     | 0.042        |

HR: Hazard ratio; CI: Confidence index; –: No data.
Although smoking was associated with coronary heart disease (CHD), this association was mediated by changes in inflammation. Inflammation, a key contributor to CHD, is influenced by smoking and is implicated in the progression of atherosclerosis. Studies have shown that smoking is associated with inflammatory markers, including C-reactive protein (CRP) and white blood cells (WBCs) [10, 18-20]. In our study, levels of WBCs and CRP were significantly higher in smokers compared with non-smokers at both procedures indicating persistent elevation of inflammatory responses. Even though results were insignificant between smokers and non-smokers concerning rapid lesion progression, smoking cessation was shown to alleviate the progression of coronary arterial stenosis in our study. Results showed that the increase in percent diameter stenosis was significantly lower in quitters compared with smokers and non-smokers. Additionally, quitters tended to have a lower incidence of rapid progression and re-vascularization of coronary non-target lesions compared with smokers and non-smokers. Similar to our results, the benefits of smoking cessation have been reported in patients with CHD before. Conroy et al. showed that cessation before the age of 40 years reduces the risk of cardiovascular death associated with continued smoking by about 90% and the relative risk of major adverse cardiac and cerebrovascular events were approximately three-fold greater in persistent smokers than in quitters. [21] In addition, inflammatory markers associated with CHD were shown to return to the similar level of a non-smoker at 5 years after quitting smoking. [22] In accordance with previous studies, our results indicated that smoking cessation is beneficial for the progression of coronary lesions even in a relatively short period of less than 2 years.

The prognosis of CHD in smokers is still debated. Prior studies have found that smokers have lower mortality than non-smokers after the onset of acute coronary syndrome or post-PCI procedure, a phenomenon known as “smoking paradox.” [23-25] Possible explanations for the higher mortality rate in non-smokers are that non-smokers are older and have a higher prevalence of comorbid factors such as hypertension and impaired left ventricle function. [11] In our study, smoking status was not an independent predictor for lesion re-vascularization and lesion-related myocardial infarction. Therefore, the phenomenon of “smoking paradox” was not observed concerning clinical outcomes of coronary non-target lesions. Furthermore, multivariable analysis showed that smokers were at a higher risk of all-cause myocardial infarction compared with non-smokers. In accordance with our results, Zhang et al. [26] showed that smoking is associated with a higher incidence of recurrent myocardial infarction in patients underwent PCI treatment.

We proposed that smoking aggravates the instability of coronary plaque which resulting in plaque rupture and subsequently myocardial infarction. As the smoking rate in China was reported to be 27.7% at 2015, [27] it is of great challenge for our government to implement stricter tobacco control policies.

This study had several limitations. First, our study was a retrospective single center study, only patients who underwent serial CAGs were enrolled. These patients might take more serious of their health and be more likely to seek for medical assistance when symptoms occur. This selection bias might have influence on the final results. Second, it is limited to evaluate lesion progression only by CAG, combined modalities such as intravascular ultrasound and optic coherence tomography should be useful to evaluate rapid lesion progression in the future studies. Third, the results needed to be confirmed in large, prospective studies.

In conclusion, the present study showed that the increase of percent diameter stenosis of coronary non-target lesions is significantly lower in quitters compared with that in smokers and non-smokers. Smoking status were not independent risk factors for lesion progression, lesion re-vascularization and lesion-related myocardial infarction but smokers were at a higher risk for all-cause myocardial infarction compared with non-smokers. Our study places further emphasis on efforts at smoking cessation to improve clinical outcomes of coronary non-target lesions.

**Funding**

This study was supported by a grant from National Nature Science Foundation of China (No. 81370327).

**Conflicts of interest**

None.

**References**

1. Schroeder SA. New evidence that cigarette smoking remains the most important health hazard. N Engl J Med 2013;368:389-390. doi: 10.1056/NEJMe1213751.
2. Teo KK, Oumpu S, Hawken S, Pandey MR, Valentin V, Hunt D, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006;368:647-658. doi: 10.1016/s0140-6736(06)69249-0.
3. McEvoy JW, Blaha MJ, DeFilippis AP, Lima JA, Blumentke DA, Hundley WG, et al. Cigarette smoking and cardiovascular events: role of inflammation and subclinical atherosclerosis from the MultiEthnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 2015;35:700-709. doi: 10.1161/atvbaha.114.304562.
4. Barua RS, Ambrose JA. Mechanisms of coronary thrombosis in cigarette smoke exposure. Arterioscler Thromb Vasc Biol 2013;33:1460–1467. doi: 10.1161/ATVBHA.112.300154.
5. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990;15:1667–1687. doi: 10.1016/0735-1097(90)92845-s.
6. Kaski JC, Chester MR, Chen L, Kattress R. Rapid angiographic progression of coronary artery disease in patients with angina pectoris. The role of complex stenosis morphology. Circulation 1995;92:2058-2065. doi: 10.1161/01.cir.92.8.2058.
7. Shah P, Babaj S, Virk H, Bikkina M, Shamoon F. Rapid progression of coronary atherosclerosis: a review. Thrombosis 2015;2015:6:34983. doi: 10.1155/2015/634983.
8. Yu M, Li W, Lu Z, Wei M, Yan J, Zhang J. Quantitative baseline CT plaque characterization of unvascularized non-culprit intermediate coronary stenosis predicts lesion volume progression and long-term prognosis: a serial CT follow-up study. Int J Cardiol 2018;264:181–186. doi: 10.1016/j.ijcard.2018.03.021.

9. Li J, Han Y, Jing J, Tu S, Chen W, Reiber JH, et al. Non-culprit coronary lesions in young patients have higher rates of atherosclerotic progression. Int J Cardiovasc Imaging 2015;31:889–897. doi: 10.1007/s10554-015-0635-9.

10. Xu YL, Li JJ, Xu B, Zhu CG, Yang YJ, Chen JL, et al. Increased plasma C-reactive protein level predicts rapid progression of non-target atherosclerotic lesions in patients with stable angina after stenting. Chin Med J 2011;124:3022–3029. doi: 10.3760/cma.j.issn.0366-6999.2011.19.013.

11. Chen T, Li W, Wang Y, Xu B, Guo J. Smoking status on outcomes after percutaneous coronary intervention. Clin Cardiol 2012;35:570–574. doi: 10.1002/clc.22004.

12. Ahmadi A, Leipsic J, Blankstein R, Taylor C, Hecht H, Stone GW, et al. Do plaques rapidly progress prior to myocardial infarction? The interplay between plaque vulnerability and progression. Circ Res 2015;117:99–104. doi: 10.1161/circresaha.117.305637.

13. Stone GW, Machara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011;364:226–235. doi: 10.1056/NEJMoa1002358.

14. Ojio S, Takatsu H, Tanaka T, Ueno K, Yokoya K, Matsubara T, et al. Considerable time from the onset of plaque rupture and/or thrombi until the onset of acute myocardial infarction in human coronary angiographic findings within 1 week before the onset of infarction. Circulation 2000;102:2063–2069. doi: 10.1161/01.cir.102.17.2063.

15. Wang L, Zhou Y, Peng P, Xu X, Yang S, Liu W, et al. Percutaneous coronary intervention rates and associated independent predictors for progression of non-target lesions in patients with diabetes mellitus after drug-eluting stent implantation. Angiology 2016;67:12–20. doi: 10.1177/0003319715578563.

16. Yano M, Miura S, Suga Y, Miyase Y, Suematsu Y, Norimatsu K, et al. Association between smoking habits and severity of coronary stenosis as assessed by coronary computed tomography angiography. Heart Vessels 2016;31:1061–1068. doi: 10.1007/s00380-015-0716-7.

17. Cheezum MK, Kim A, Bittencourt MS, Kassop D, Nissen A, Thomas DM, et al. Association of tobacco use and cessation with coronary atherosclerosis. Atherosclerosis 2017;257:201–207. doi: 10.1016/j.atherosclerosis.2016.11.016.

18. Zouridakis EG, Schwartzman R, Garcia-Moll X, Cox ID, Fredericks S, Holt DW, et al. Increased plasma endothelin levels in angina patients with rapid coronary artery disease progression. Eur Heart J 2001;22:1578–1584. doi: 10.1053/euhj.2000.2588.

19. Wang JJ, Fan Y, Zhu Y, Zhang JD, Zhang SM, Wan ZF, et al. Biomarkers enhance the long-term predictive ability of the KAMIR risk score in Chinese patients with ST-elevation myocardial infarction. Chin Med J 2019;132:30–41. doi: 10.1097/cm9.0000000000000145.

20. Hu XM, Chen X, Pang HY, Liu HH, Chen PP, Shi JL, et al. Plasma levels of receptor interacting protein kinase-3 correlated with coronary artery disease. Chin Med J 2019;132:1400–1405. doi: 10.1097/cm9.0000000000000225.

21. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987–1003. doi: 10.1016/j.choh.2015.01.032.

22. Bakhru A, Erlinger TP. Smoking cessation and cardiovascular disease risk factors: results from the Third National Health and Nutrition Examination Survey. PLoS Med 2005;2:e160. doi: 10.1371/journal. pmed.0020160.

23. Gupta T, Kolte D, Khera S, Harikrishnan P, Mujib M, Aronow WS, et al. Smoker’s Paradox in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Am Heart Assoc 2016;5:e003370. doi: 10.1161/jaha.10161/p003370.

24. Weis G, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, et al. Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction—the smoker’s paradox revisited. Am Heart J 2010;50:358–364. doi: 10.1016/j.ahj.2004.01.032.

25. Zhang H, Sun S, Tong L, Li R, Cao XH, Zhang BH, et al. Effect of cigarette smoking on clinical outcomes of hospitalized Chinese male smokers with acute myocardial infarction. Chin Med J 2010;123:2807–2811. doi: 10.3760/cma.j.issn.0366-6999.2010.20.011.

26. Zhang YJ, Iqbal J, van Klaveren D, Campos CM, Holmes DR, Kappetein AP, et al. Smoking is associated with adverse clinical outcomes in patients undergoing revascularization with PCI or CABG: the SYNTAX trial at 5-year follow-up. J Am Coll Cardiol 2015;65:1107–1115. doi: 10.1016/j.jacc.2015.01.014.

27. Goodchild M, Zhang R. Tobacco control and Healthy China 2030, Tob Control 2019;28:409–413. doi: 10.1136/tobaccocontrol-2018-054372.

How to cite this article: Xu HB, Wang J, Chen JL, Guo C, Yuan JS, Duan X, Hu FH, Yang WX, Luo XL, Liu R, Cui JG, Liu SW, Gao XJ, Chun YS, Qiao SB. Impacts of smoking status on the clinical outcomes of coronary non-target lesions in patients with coronary heart disease: a single-center angiographic study. Chin Med J 2020;133:2295–2301. doi: 10.1097/ CM9.00000000000001024.